Caixin
Sep 29, 2022 03:31 AM
BUSINESS

Merck in Deal With Sinopharm to Bring Covid Antiviral to China

The drug, which Merck co-developed with Ridgeback Biotherapeutics LP, has not yet been approved for use in China.
The drug, which Merck co-developed with Ridgeback Biotherapeutics LP, has not yet been approved for use in China.

(Bloomberg) — Merck & Co. struck a deal with Chinese state-owned drugmaker Sinopharm to import and market its antiviral molnupiravir in China, a tentative sign the country is considering more foreign Covid-19 medicines.

Merck and Sinopharm are also evaluating the feasibility of a technology transfer that would facilitate production, supply and commercialization of molnupiravir in China, according to Sinopharm subsidiary China National Biotec Group, which signed the agreement with Merck.

You've accessed an article available only to subscribers
VIEW OPTIONS
Share this article
Open WeChat and scan the QR code